The National Agency for Food and Drug Administration and Control (NAFDAC) has announced the immediate withdrawal, suspension, and cancellation of 101 pharmaceutical products across Nigeria. The move prohibits their manufacture, importation, exportation, distribution, advertisement, sale, and use nationwide.
The announcement, made on NAFDAC’s official X (formerly Twitter) handle on Tuesday, September 30, 2025, lists the affected products on the agency’s website. The list includes widely used medicines and health products, ranging from antimalarials such as artemether/lumefantrine formulations to cardiovascular drugs like valsartan, insulin and growth-hormone injectables (Norditropin), diabetes medications (Januvia/Janumet), inhalers, and eye drops.
Prominent drugs on the list include Abacavir tablets, Amaryl tablets, Aprovasc tablets, Artemether/Lumefantrine, ASAQ (Artesunate amodiaquine Winthrop) tablets, Combination 3 tablets, and Amlodipine, among others. These products are manufactured by leading pharmaceutical companies, including Sanofi Aventis Nigeria Ltd, Novartis Nigeria Limited, Bayer East Africa Limited, Healthline Limited, and Fensyl MHP Consulting Ltd.
“This is to inform the General Public that the following products are approved for withdrawal, suspension, and cancellation by NAFDAC. They are no longer permitted for manufacture, importation, exportation, distribution, advertisement, sale, or use within Nigeria,” the agency said.
NAFDAC explained that a product’s Certificate of Registration may be withdrawn at the manufacturer’s request, suspended if regulatory conditions are unmet, or cancelled if revoked by the agency.
The regulatory action comes amid growing global concerns over substandard and falsified medical products, which the World Health Organization (WHO) estimates affect 1 in 10 medicines in low- and middle-income countries. NAFDAC recently called for pharmacists’ collaboration to curb the proliferation of such products, which pose serious risks to public health.
